



## **Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference**

September 25, 2017

VANCOUVER, British Columbia and WARMINSTER, Pa., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the 2017 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 in New York.

### **About Arbutus**

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### **Contact Information**

#### **Investors**

Adam Cutler  
Senior Vice President, Corporate Affairs  
Phone: 604-419-3200  
Email: [acutler@arbutusbio.com](mailto:acutler@arbutusbio.com)

Tiffany Tolmie  
Manager, Investor Relations  
Phone: 604-419-3200  
Email: [ttolmie@arbutusbio.com](mailto:ttolmie@arbutusbio.com)

#### **Media**

David Schull  
Russo Partners  
Phone: 858-717-2310  
Email: [david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

#### **[Primary Logo](#)**

Source: Arbutus Biopharma Corporation